<DOC>
	<DOCNO>NCT01805180</DOCNO>
	<brief_summary>The purpose study compare procedure collection PMN cell Terumo BCT 's Spectra Optia® COBE® Spectra Apheresis Systems .</brief_summary>
	<brief_title>Evaluation Spectra Optia PMN Cell Collection Procedure</brief_title>
	<detailed_description>The purpose study compare procedure collection granulocyte/ polymorphonuclear ( PMN ) cell Terumo BCT 's Spectra Optia® COBE® Spectra Apheresis Systems establish non-inferiority Spectra Optia Apheresis System respect primary study endpoint , granulocyte/PMN cell collection efficiency .</detailed_description>
	<criteria>Acceptable health status vital sign per AABB blood donation guideline permit blood donation , include : 1 . Blood pressure ≥ 90/50 ≤ 200/120 mmHg , 2 . Pulse &gt; 40 &lt; 100 beats/min , 3 . Temperature &lt; 99.5ºFahrenheit ( F ) . Able read , understand , sign English inform consent form . Age ≥ 18 year . Weight ≥ 50kg &lt; 227kg . Male nonpregnant , nonnursing female ( negative serum pregnancy test screen negative urine pregnancy test prior mobilization ) . Acceptable screen laboratory test result prior first PMN cell mobilization , include : 1 . WBC count range : 3,50010,800/uL , 2 . Hematocrit range : 3865 % , 3 . Platelet count range : 150,000400,000/uL , 4 . Coagulation test : PT great 1.1 time upper limit local laboratory reference range ; PTT great 1.2 time upper limit local laboratory reference range , 5 . Serum electrolyte concentration : potassium range 3.65.1 mmol/L ; calcium range 8.510.3 mg/dL , 6 . Serum creatinine great 1.5mg/dL , 7 . ALT great 1.5 time upper limit local laboratory reference range . *** Up two ( 2 ) screen laboratory test result may fall outside range , judgment principal investigator designee , constitute significant risk subject . Any excused deviation list summarized final report . *** Adequate dual peripheral venous access allow collection granulocyte ( PMN cell ) return remain cell , platelet plasma . If male , willing use condom sexual relation female partner child bear potential 48 hour follow GCSF injection . If female , willing use medicallyacceptable contraceptive 48 hour follow GCSF injection . Positive screen following : HIV , HBV ( except isolate HB core Ab reactivity ) , HCV , HTLV , Syphilis West Nile Virus . Currently pregnant breastfeeding . Collection loss specific volume whole blood blood component specify timeframes : 1. 550mL whole blood within prior 56 day , 2. 3L whole blood 1.5L red blood cell within prior 12 month , 3. 12L plasma within prior 12 month , 4. leukapheresis within prior six week , 5. plateletpheresis within prior 48 hour two within prior 7 day twentyfour within last 12 month , 6. plasmapheresis within prior 48 hour two within prior 7 day . History congestive heart failure . History uncontrolled hypertension ( SBP/DBP &gt; 200/120 mmHg ) . History suspicion active , peptic ulcer disease . History diabetes mellitus . History hematologic malignancy chronic hematologic disorder . Family history ( parent , sibling , child ) hematologic malignancy . History deep vein thrombosis venous thromboembolism , bleed disorder . History sickle cell disease positive SickleDex screen . History iritis episcleritis . History autoimmune condition disorder , unless approve principal investigator . Presence psychological trait , physiological medical condition , opinion investigator , would make subject unlikely tolerate procedure complete study . History use/anticipated need lithium . Received GCSF injection prior 4 month . Known hypersensitivity ethylene oxide . Known hypersensitivity GCSF hypersensitivity E. coliderived product . Known hypersensitivity HES corn . Concurrent participation another clinical trial participation clinical trial within past 30 day . Subject treat calcium channel blocker and/or antiepileptic medication . Note : This apply Subjects Bonfils Blood Center whose collected product undergo neutrophil function testing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>